Fastest customizable press release news feed in the world
Tainan City, Taiwan, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (NASDAQ:ADVB) (the "Company" or "Advanced Biomed"), a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicine and advanced diagnostics, today announced a reverse stock split of the Company's issued and outstanding common stock at a ratio of 1 for 20 shares (the "Reverse Split"), which will take effect at the open of The Nasdaq Stock Market ("Nasdaq") on February 20, 2026. In accordance with Section 78.320.2 of the Nevada Revised Statutes, on January 12, 2026, the holders of a majority of the outstanding voting power of the Company approved by written co
Tainan, Taiwan, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (NASDAQ:ADVB) (the "Company", "Advanced Biomed"), a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicine and advanced diagnostics, today announced the Company has entered into a clinical research collaboration agreement (the "Agreement") with Chi‑Mei Medical Center to initiate a 120‑case feasibility study designed to evaluate the predictive accuracy of the Company's A+PerfusC™, a perfusion-based 3D cell culture in a compact incubator designed to replicate human physiological conditions in vitro. The feasibility study is a non‑interventional clinical resea
Tainan City, Taiwan, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (NASDAQ:ADVB) (the "Company", "Advanced Biomed"), a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicine and advanced diagnostics, today announced that on December 23, 2025, it entered into an agreement (the "Agreement") with an unrelated third party, Wei Ha Hui (the "Buyer"), pursuant to which the Company agreed to sell 100% of the issued and outstanding shares of Advanced Biomed (HK) Limited, a Hong Kong company and a wholly owned subsidiary of the Company (the "Hong Kong Subsidiary"), for an aggregate purchase price of US$23,000 based on a valuatio
[Tainan City], Taiwan, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (NASDAQ:ADVB) (the "Company", "Advanced Biomed"), a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicine and advanced diagnostics, today announced the launch of its A+PerfusC™ system, a compact, all‑in‑one perfusion 3D cell culture incubator designed to replicate human physiological conditions in vitro. (A+PerfusC™ 3D System-a perfusion-based 3D cell culture in a compact incubator) The A+PerfusC™ platform integrates automated perfusion with environmental control in a compact format that can be mounted directly onto a microscope for real‑time ob
8-K - Advanced Biomed Inc. (0001941029) (Filer)
8-K - Advanced Biomed Inc. (0001941029) (Filer)
8-K - Advanced Biomed Inc. (0001941029) (Filer)
8-K - Advanced Biomed Inc. (0001941029) (Filer)
8-K - Advanced Biomed Inc. (0001941029) (Filer)
10-Q - Advanced Biomed Inc. (0001941029) (Filer)
8-K/A - Advanced Biomed Inc. (0001941029) (Filer)
8-K - Advanced Biomed Inc. (0001941029) (Filer)
8-K - Advanced Biomed Inc. (0001941029) (Filer)
DEF 14C - Advanced Biomed Inc. (0001941029) (Filer)